检索结果-南通市图书馆

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2023年第2期20卷 129-146页

作者： Ping Li Yang Liu Yun Liang Jian Bo Sujun Gao Yongxian Hu Yu Hu He Huang Xiaojun Huang Hongmei Jing Xiaoyan Ke Jianyong Li Yuhua Li Qifa Liu Peihua Lu Heng Mei Ting Niu yongping song Yuqin song Liping Su Sanfang Tu Jianxiang Wang Depei Wu Zhao Wang Kailin Xu Zhitao Ying Qingming Yang Yajing Zhang Fengxia Shi Bin Zhang Huilai Zhang Xi Zhang Mingfeng Zhao Weili Zhao Xiangyu Zhao Liang Huang Jun Zhu Wenbin Qian Weidong Han Aibin Liang Department of Hematology Shanghai Tongji HospitalTongji University School of MedicineShanghai 200065China Department of Bio-therapeutic Chinese PLA General HospitalBeijing 100853China Department of Hematology The Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310009China Department of Hematology Chinese PLA General HospitalBeijing 100853China Department of Hematology The First Hospital of Jilin UniversityChangchun 130012China Center for Bone Marrow Transplantation The First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310058China Institute of Hematology Union Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Peking University People’s Hospital&Peking University Institute of Hematology Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Department of Hematology Lymphoma Research CenterPeking University Third HospitalBeijing 100191China Department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjing 210029China Department of Hematology Zhujiang HospitalSouthern Medical UniversityGuangzhou 510280China Department of Hematology Nanfang HospitalSouthern Medical UniversityGuangzhou 510515China Lu Daopei Institute of Hematology Beijing 101102China Department of Hematology West China HospitalSichuan UniversityChengdu 610041China The Affiliated Cancer Hospital of Zhengzhou University Zhengzhou 450008China Department of Lymphoma Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Hematology Shanxi Cancer HospitalTaiyuan 030013China State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesDivision of Pediatric Blood Disease CenterInstitute of Hematology&Blood Disease HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianj

Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-cell products and advances in CAR T cell therapy,CAR T cells are expected to be used in a growing number of ***,CAR T-cell-associated toxicities can be severe or even fatal,thus compromising the survival benefit from this *** and studying the clinical management of these toxicities are *** contrast to other hematological malignancies,such as acute lymphoblastic leukemia and multiple myeloma,anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features,most notably local cytokine-release syndrome(CRS).However,previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for ***,we developed this consensus for the prevention,recognition,and management of these toxicities,on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese *** consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management,and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.

关键词： CAR T-cell therapy B-cell non-Hodgkin lymphoma toxicity cytokine-release syndrome clinical management

Application of HACCP in Producting Process of Tartary Buckwheat

在线全文

学校读者我要写书评

暂无评论

Agricultural Biotechnology 2018年第2期7卷 151-154页

作者： yongping song keyong ZHANG Pengyan XIE Min GUO School of Economics and Management North University of China

Food safely has always been the focus of consumer＇s attention since the successful accession of China to the WTO ,and many Chinese food processing enterprises have transformed from small workshop into a large-scale modern enterprises capable of processing continuously ,which requires us to constantly update and improve a series of food safety control system,In this paper,we studied the application of HACCP system in the manufacturing process of tartary buchwheat tea and analyzed hazards in the process of bitter buckwheat tea,and concluded that purchase of raw material,screening and grading ,soaking,cooking ,drying and sterilization ,shelling,packaging and storage of ginished product are eight links as critical control points ,Based on this,corrective measures were proposed,and a detailed HACCP plan was developed.

关键词： Tartary buckwheat tea Food safety HACCP Application

靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

白血病．淋巴瘤 2022年第2期31卷 68-72页

作者：闫艳林全德宋永平郑州大学附属肿瘤医院河南省肿瘤医院血液科河南省血液病研究所郑州450008

以嵌合抗原受体T细胞(CAR-T)疗法为代表的细胞治疗在多发性骨髓瘤(MM)治疗领域取得了很多突破进展,尤其是靶向B细胞成熟抗原(BCMA)的自体CAR-T、双特异性CAR-T和通用型CAR-T等在多项MM的临床研究中均获得了良好疗效,第63届美国血液学会... 详细信息

以嵌合抗原受体T细胞(CAR-T)疗法为代表的细胞治疗在多发性骨髓瘤(MM)治疗领域取得了很多突破进展,尤其是靶向B细胞成熟抗原(BCMA)的自体CAR-T、双特异性CAR-T和通用型CAR-T等在多项MM的临床研究中均获得了良好疗效,第63届美国血液学会年会上更新了多项相关临床研究数据,结果令人鼓舞。

关键词：多发性骨髓瘤嵌合抗原受体T细胞 B细胞成熟抗原

基于电力大数据的供电服务指挥平台构建技术研究

在线全文

学校读者我要写书评

暂无评论

电子器件 2022年第3期45卷 753-759页

作者：武国亮王瑾宋涌平王琼国网介休市供电公司山西晋中032000

随着配电网中网架结构日益复杂、一二次设备深度融合与电力数据指数化增长,配电网运检管理、生产调度、安全监控等电力业务应用难度迅速增加。为了适应多源异构电力数据场景下的电力多重业务需求,基于通信协议交互融合技术、主动服务管... 详细信息

随着配电网中网架结构日益复杂、一二次设备深度融合与电力数据指数化增长,配电网运检管理、生产调度、安全监控等电力业务应用难度迅速增加。为了适应多源异构电力数据场景下的电力多重业务需求,基于通信协议交互融合技术、主动服务管理技术与电力大数据技术,构建统一控制、格式兼容、信息共享的供电服务指挥平台,实现软件、硬件、数据等多维复杂结构。从而在不同业务场景下,实现海量数据一体化组织和管理。通过对配电网电力大数据在智能需求响应的实际应用算例,证明了该服务指挥平台在配电网稳定运行管理中的重要作用。

关键词：电力大数据供电服务指挥数据融合智能需求响应

在线全文

学校读者我要写书评

暂无评论

超宽带雷达建筑物结构稀疏成像

雷达学报（中英文） 2018年第3期7卷 275-284页

作者：金添宋勇平国防科技大学电子科学学院长沙410073

超宽带雷达具备穿透墙体获得建筑物内部结构布局的能力,为建筑物内人员探测定位提供更丰富的信息。传统成像常存在较为严重的旁瓣,而且墙后目标成像位置也会受墙体影响而产生偏移。为提高成像质量,稀疏重构技术被引入穿墙成像领域,但传... 详细信息

超宽带雷达具备穿透墙体获得建筑物内部结构布局的能力,为建筑物内人员探测定位提供更丰富的信息。传统成像常存在较为严重的旁瓣,而且墙后目标成像位置也会受墙体影响而产生偏移。为提高成像质量,稀疏重构技术被引入穿墙成像领域,但传统方法对弱散射目标的重构概率较低。该文提出结合相干因子(Coherence Factor,CF)加权的稀疏重构方法,在稀疏重构提取支撑集的过程中,利用CF增强成像的结果来提高支撑集原子的正确性,降低稀疏重构过程中强散射目标旁瓣的影响,最终提高场景中弱散射目标的重构概率。同时建立了多层墙体位置校正模型,将场景校正放到稀疏重构之后进行,从而以较低的计算复杂度降低墙体定位误差。实测数据处理结果表明,相比于传统的稀疏成像方法,相同的数抽取比例下,该文提出的方法能够有效提高场景中弱散射目标重构概率,并将建筑物内部墙体定位误差降低至10 cm以内。

关键词：超宽带雷达穿墙成像稀疏重构建筑物结构

慢性粒细胞白血病:最新研究进展和未来发展方向

在线全文

学校读者我要写书评

暂无评论

白血病．淋巴瘤 2023年第2期32卷 74-78页

作者：李旭东张龑莉宋永平郑州大学第一附属医院血液科郑州450052 郑州大学附属肿瘤医院血液科郑州450003

慢性粒细胞白血病(CML)是一种由BCR-ABL融合蛋白驱动的恶性血液病。靶向BCR-ABL的酪氨酸激酶抑制剂(TKI)的问世彻底改变了CML的治疗格局,从2001年第一代TKI伊马替尼获批,到第四代TKI药物相继出现,CML患者从中获益匪浅。即便如此,仍有很... 详细信息

慢性粒细胞白血病(CML)是一种由BCR-ABL融合蛋白驱动的恶性血液病。靶向BCR-ABL的酪氨酸激酶抑制剂(TKI)的问世彻底改变了CML的治疗格局,从2001年第一代TKI伊马替尼获批,到第四代TKI药物相继出现,CML患者从中获益匪浅。即便如此,仍有很多CML患者因为耐药、停药后复发或疾病进展等原因导致治疗失败,一些患者则需要进行多线TKI治疗,难以获得长期缓解。覆盖更多突变谱系的新药物的研发、更优化的治疗策略以及患者的停药相关研究仍然是CML治疗关注的热点。文章就第64届美国血液学年会关于CML的研究进展进行介绍。

关键词：慢性粒细胞白血病酪氨酸激酶抑制剂治疗

在线全文

学校读者我要写书评

暂无评论

民国时期云南怒江地区的三部方志

史学史研究 2000年第4期 67-71页

作者：宋永平云南省地方志办公室云南昆明650118

民国时期云南怒江地区的三部地方志 ,第一次全面系统地记载了该地区自然和社会的历史与现状 ,在思想观念、资料内容和体例方法上取得一定的成就 ,具有较高的史料价值。在这三部方志中 ,除《泸水志》石印成册外 ,《纂修上帕沿边志》、《... 详细信息

民国时期云南怒江地区的三部地方志 ,第一次全面系统地记载了该地区自然和社会的历史与现状 ,在思想观念、资料内容和体例方法上取得一定的成就 ,具有较高的史料价值。在这三部方志中 ,除《泸水志》石印成册外 ,《纂修上帕沿边志》、《征集菖蒲桶沿边志》

关键词：民国时期云南怒江地区地方志

维奈托克联合TKI及含地塞米松小剂量化疗对复发/难治Ph+急性B淋巴细胞白血病的疗效分析

在线全文

学校读者我要写书评

暂无评论

中华医学杂志 2022年第10期102卷 745-748页

作者：田云艾昊纪旭魏旭东宋永平尹青松郑州大学附属肿瘤医院血液科郑州450008

分析郑州大学附属肿瘤医院采用Bcl-2抑制剂维奈托克联合酪氨酸激酶抑制剂(TKI)及含地塞米松小剂量化疗方案治疗5例复发/难治(R/R)费城染色体阳性急性B淋巴细胞白血病(Ph+B-ALL)的临床资料,并评估疗效及安全性。5例患者中2例伴T315I突变... 详细信息

分析郑州大学附属肿瘤医院采用Bcl-2抑制剂维奈托克联合酪氨酸激酶抑制剂(TKI)及含地塞米松小剂量化疗方案治疗5例复发/难治(R/R)费城染色体阳性急性B淋巴细胞白血病(Ph+B-ALL)的临床资料,并评估疗效及安全性。5例患者中2例伴T315I突变采用帕纳替尼,3例采用氟马替尼。结果显示,4例微小残留病(MRD)阳性患者,3例短期内达完全分子学缓解(CMR),1例无效;1例形态学复发患者1个月达完全缓解(CR),总有效率为80%。不良反应包括皮肤色素沉着、胃肠道反应、乏力和Ⅰ~Ⅱ度骨髓抑制。

关键词：白血病,幼淋巴细胞,B细胞酪氨酸激酶抑制剂微小残留病复发难治

ERCC-1、sruvivin表达与含顺铂方案-线化疗治疗晚期肺腺癌患者疗效和预后关系(英文)

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2009年第5期8卷 265-268页

作者： Xiaobing Chen Suxia Luo Ning Li yongping song Junjie Zen The First Affiliated Hospital of Zhengzhou University He＇nan Province Tumor Hospital Zhengzhou 450008 China Medicine Department He＇nan Province Tumor Hospital Zhengzhou 450008 China

Objective:We analyzed the relationship between the expression of ERCC-1(excisition repair cross complement-1), survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung ***:Immunohistochemical(IHC) method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line *** response rate and survival time were analyzed according to the expression of ERCC-1 and ***:Only 77 patients could be reviewed by IHC *** expression rates of ERCC-1 and survivin were 33.77% and 53.25 % *** worse response rate and shorter TTP/ PFS could be identified in ERCC-1 positive *** with positive expression of survivin had worse survival ***:Expression of ERCC-1 may be a molecular marker of cisplatincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma *** expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.

关键词： survivin 晚期肺腺癌预后不良化疗治疗 Survivin表达免疫组织化学组织化学染色血小板减少性